Last reviewed · How we verify

Erdafitinib Intravesical Delivery System

Janssen Pharmaceutical K.K. · Phase 1 active Small molecule Quality 0/100

Erdafitinib Intravesical Delivery System is a Small molecule drug developed by Janssen Pharmaceutical K.K.. It is currently in Phase 1 development. Also known as: JNJ-42756493.

At a glance

Generic nameErdafitinib Intravesical Delivery System
Also known asJNJ-42756493
SponsorJanssen Pharmaceutical K.K.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Erdafitinib Intravesical Delivery System

What is Erdafitinib Intravesical Delivery System?

Erdafitinib Intravesical Delivery System is a Small molecule drug developed by Janssen Pharmaceutical K.K..

Who makes Erdafitinib Intravesical Delivery System?

Erdafitinib Intravesical Delivery System is developed by Janssen Pharmaceutical K.K. (see full Janssen Pharmaceutical K.K. pipeline at /company/janssen-pharmaceutical-k-k).

Is Erdafitinib Intravesical Delivery System also known as anything else?

Erdafitinib Intravesical Delivery System is also known as JNJ-42756493.

What development phase is Erdafitinib Intravesical Delivery System in?

Erdafitinib Intravesical Delivery System is in Phase 1.

Related